The Preventive Care Gap in U.S. Insurance — and How Taiwan Fills It

The Affordable Care Act guarantees Americans coverage for "preventive care" without cost-sharing — but that phrase is narrower than most people assume. The U.S. Preventive Services Task Force (USPSTF) maintains a list of Grade A and B services that insurers must cover, and the list is short: colonoscopy starting at 45, mammography starting at 40, lung CT for heavy smokers 50–80, abdominal aortic aneurysm screening for men 65–75 with a smoking history. Full-body MRI, coronary calcium scoring outside high-risk profiles, advanced biomarker panels, and DEXA scans for adults under 65 are all explicitly outside the cost-share-free guarantee.

That gap — between what the U.S. system pays for and what evidence-based prevention actually requires — is the void Taiwan fills. This article covers the policy and clinical mechanics. For the dollar math, HSA mechanics, and out-of-pocket comparisons, see our cost & insurance companion piece.

How the USPSTF actually works

The USPSTF is an independent panel of 16 volunteer experts in primary care and prevention, convened by the Agency for Healthcare Research and Quality (AHRQ) under HHS. It does not regulate. It does not pay claims. What it does is publish letter grades that, by virtue of Section 2713 of the ACA, become legally binding on insurers:

• Grade A — high certainty of substantial net benefit. Insurers must cover, no cost-sharing.
• Grade B — high certainty of moderate benefit, or moderate certainty of moderate-to-substantial benefit. Same coverage rule as A.
• Grade C — small net benefit. Offer selectively. Not mandated coverage.
• Grade D — no benefit or harms outweigh benefits. Discourage.
• Grade I — insufficient evidence to assess balance of benefits and harms. Insurers typically use this to decline cost-share-free coverage.

Grade decisions hinge on cost-effectiveness analysis expressed in dollars per quality-adjusted life year (QALY). The informal U.S. willingness-to-pay threshold sits in the $50,000 – $150,000 per QALY range; the UK's NICE uses a tighter £20,000 – £30,000 (~$25K – $38K) bar. When a screening test costs $3,000 – $5,000 in U.S. cash-pay, the dollars-per-QALY math rarely clears the threshold for asymptomatic adults at average risk — even when the clinical signal is real.

Here's the part most patients don't realize: those QALY calculations are anchored to U.S. price assumptions. When the same coronary calcium score CT runs ~$300 in Taipei instead of $400 – $1,000 in Manhattan, when a full-body MRI runs ~$800 – $1,200 instead of $3,000 – $5,000, the cost-effectiveness ratios can flip from "not recommended" to "highly favorable." The clinical evidence doesn't change. The denominator does. That's why a screening protocol the USPSTF rates "I" can simultaneously be standard of care in Taiwan and cash-only specialty in the United States.

Five-year survival by cancer stage — the actual numbers

Why does the screening gap matter clinically? Because catching a cancer at stage 1 vs stage 4 changes the survival curve by an order of magnitude. The data below draws from the American Cancer Society's 2024 Cancer Facts & Figures and the NCI SEER program; numbers are 5-year relative survival rounded to whole percentages.

The window between stage 1 and stage 4 is exactly what advanced screening targets. For pancreatic — typically asymptomatic until late — the difference between catching it on a routine MRI and presenting with symptoms is between a 44% and a 3% survival probability. For gastric and esophageal, both notoriously silent in early stages and rarely caught by symptom-driven workups, the spread is similarly steep. That delta is the entire clinical case for asymptomatic preventive imaging.

What's covered vs what's not — the side-by-side

Why advanced biomarkers matter (and why they're not on the standard panel)

The standard U.S. lipid panel — total cholesterol, HDL, LDL (calculated, not measured), triglycerides — was designed in the 1970s. It is, in 2026 terms, a blunt instrument. Modern preventive cardiology relies on a deeper set of markers that the routine LabCorp / Quest preventive panels still don't include by default:

• ApoB — apolipoprotein B is the protein wrapper around every atherogenic particle (LDL, VLDL, IDL, Lp(a), chylomicron remnants). It counts particles directly rather than estimating cholesterol cargo. Most U.S. lipid guidelines now recognize ApoB as superior to LDL-C for risk stratification, especially in patients with metabolic syndrome or insulin resistance, where LDL can be misleadingly normal. Optimal target for primary prevention sits below ~80 mg/dL; for high-risk secondary prevention, below ~65 mg/dL.
• Lp(a) — lipoprotein little-a is genetically determined and largely unaffected by lifestyle or statins. Roughly 20% of the global population has elevated Lp(a) (>50 mg/dL or >125 nmol/L), independently doubling cardiovascular risk. Tested once in a lifetime is enough. The U.S. preventive system rarely orders it because there's no cheap drug to lower it — but the information itself shapes how aggressively a patient should manage every other modifiable risk factor.
• hs-CRP — high-sensitivity C-reactive protein, a marker of vascular inflammation. Below 1 mg/L is low risk; 1–3 mg/L is intermediate; above 3 mg/L is high. Distinct from general inflammation: hs-CRP specifically tracks the inflammatory state implicated in atherosclerotic plaque progression.
• Fasting insulin and the Kraft insulin response test — fasting glucose can sit normal for 5–10 years while insulin secretion runs 3–5x baseline trying to keep it there. Fasting insulin (target <7 µIU/mL for metabolic health) catches the early hyperinsulinemia phase of insulin resistance long before HbA1c moves. The Kraft test, a multi-hour OGTT with timed insulin measurement, maps the response curve directly. Almost no U.S. primary care practice runs either as a screening test.

None of these are exotic. They run on the same equipment that already drew your blood. They're absent from the routine U.S. preventive panel because USPSTF has not graded them A or B — and because ApoB and Lp(a) didn't exist as billable codes in primary care reimbursement schedules until very recently.

Calcium score: the most over- and under-prescribed test in U.S. cardiology

Coronary artery calcium (CAC) scoring is a low-radiation chest CT that quantifies calcified plaque in the coronary arteries, expressed in Agatston units:

• 0 — no detectable calcified plaque. The single most reassuring piece of cardiac data an asymptomatic adult can have. 10-year cardiac event risk roughly halves vs. predicted from traditional risk calculators.
• 1–99 — minimal plaque. Often the trigger for statin therapy in borderline-risk patients.
• 100–399 — moderate plaque. High enough to recommend statin and aggressive lifestyle intervention regardless of LDL.
• 400+ — extensive plaque. Patient is in the top decile of cardiovascular risk; functional testing (stress echo, CCTA) often follows.

The MESA (Multi-Ethnic Study of Atherosclerosis) cohort produced the MESA Risk Score, which integrates CAC into 10-year coronary heart disease risk estimation more accurately than any traditional calculator. Yet the USPSTF still grades CAC "I" for asymptomatic screening — meaning insufficient evidence. The reason isn't that CAC doesn't predict events; it does. The argument turns on whether knowing the score changes outcomes more than starting a statin would have anyway. For patients with a 0 score, the data is overwhelming: it's a safe deprescribing signal. For high scores in asymptomatic adults, controversy remains over whether downstream cath labs and stents actually extend life.

This nuance gets lost in the U.S. system, which generally responds to "I" with "denied." In Taiwan it gets ordered routinely as one component of a layered screening read.

What "incidentaloma" really means

Preventive imaging is not free of downsides. The most-cited concern is the incidentaloma — a finding that's almost certainly benign but technically not normal. The literature suggests 10–30% of asymptomatic full-body MRIs surface at least one incidental finding: a small cyst, a hepatic hemangioma, a Tarlov cyst on a sacral nerve root, a benign thyroid nodule under 1 cm.

The clinical question is what to do next. Most incidentalomas warrant a single follow-up imaging study at 6–12 months, then nothing. A small fraction (low single-digit percent) trigger biopsy or further workup. An even smaller fraction lead to procedures that, in retrospect, didn't change life expectancy — the overdiagnosis problem the USPSTF is genuinely trying to avoid in its grading.

This is why the interpretation layer of a screening matters as much as the imaging layer. A radiologist who reports "0.6 cm hepatic hemangioma — benign, no follow-up needed" is doing entirely different clinical work than one who reports "incidental hepatic lesion, recommend MRI with contrast in 3 months." Both are technically defensible; one creates downstream care, the other doesn't. Patients evaluating preventive screening abroad should ask specifically how the report handles incidental findings — Taiwan partner hospitals typically follow ACR (American College of Radiology) White Paper guidance on incidental findings, which is the most parsimonious widely-accepted standard.

Patient persona: the asymptomatic CEO

The demographic showing up at Taiwan preventive screening tilts heavily toward executives 45–65 with discretionary income, often on HSA-eligible plans, frequently with strong family histories that didn't quite hit the USPSTF risk thresholds. The pattern is consistent enough to describe:

A 52-year-old male founder, family history of MI in his father at 58, runs marathons, eats clean, LDL 110, never smoked, BP 124/78, ASCVD risk calculator says ~4% 10-year risk — below the 7.5% threshold most U.S. guidelines use to recommend statin. His U.S. PCP says "looks great, see you next year." He flies to Taiwan, does a comprehensive screening morning, learns: ApoB 105 (high), Lp(a) 180 nmol/L (high), CAC score 156 (moderate plaque, 75th percentile for age). His actual cardiac risk is roughly triple what the standard calculator suggested. He goes home and starts a statin and a PCSK9 conversation.

What most learn is reassuring — calcium 0, normal panels, normal MRI. A meaningful subset find actionable cardiac risk that traditional U.S. screening missed. A small percentage find an early-stage cancer (kidney, thyroid, and breast lead the list of incidental cancer detections in published full-body MRI cohorts). The mix matters: preventive imaging isn't expected to find disease in most patients. It's expected to provide a high-certainty baseline against which the next decade of monitoring becomes more meaningful.

What "preventive" looks like clinically in Taiwan

At our partner hospitals, a preventive screening morning isn't a single test — it's a layered protocol that triangulates across imaging, biomarkers, and physician interpretation:

1. Imaging layer: full-body MRI (radiation-free, ~14 organ systems), low-dose lung CT (radiation dose comparable to ~6 months of natural background exposure), coronary calcium score CT, ultrasound (carotid, thyroid, abdomen, pelvis), optional whole-spine MRI
2. Biomarker layer: 60+ markers including ApoB, Lp(a), hs-CRP, HbA1c, fasting insulin, fasting glucose, full lipid panel, hormone panel (testosterone, DHEA-S, estradiol where appropriate), thyroid panel, tumor markers (CEA, AFP, PSA, CA-125, CA 19-9), vitamin D, B12, ferritin, homocysteine
3. Functional layer: DEXA scan for body composition + bone density, ECG, optional echocardiography, optional exercise stress test
4. Interpretation layer: 30-minute physician debrief in English, written report with U.S.-equivalent CPT procedure references, DICOM imaging files for U.S. radiologist re-read if desired

"My U.S. physical was a blood pressure check, fasting lipid panel, and a five-minute conversation. My Taiwan physical was a 4-hour mapping of my body that gave me a calcium score, a hormone panel, a baseline DEXA, and a doctor sitting with me for 30 minutes the next morning explaining what it all meant. The two visits answered different questions." — Eileen W., 40, executive coach, New York

Integration with U.S. primary care: the actual handoff

"Just hand the report to your PCP" sounds clean and frequently isn't. U.S. primary care physicians average 15-minute appointments and run on quality metrics that don't include reviewing 40-page outside imaging reports. Patients who succeed at integrating Taiwan findings into U.S. care typically do three things:

1. Send the PDF report and a one-page summary ahead of the visit, not at the visit. Front-desk staff can route it to the EHR before the doctor walks in. Bringing a stack of paper at the appointment guarantees a "we'll review and call you" deferral.
2. Identify the 2–3 actionable findings and frame the visit around those, not the full report. "My calcium score was 156 and my ApoB was 105 — I'd like to discuss whether to start a statin" is a tractable conversation. "Here's everything they did, what should I do?" is not.
3. Be ready for specialist referrals when the PCP isn't comfortable interpreting. Cardiology for elevated CAC or abnormal Lp(a). Endocrinology for hormone or insulin findings. Oncology only if a finding genuinely warrants it (rare). Many PCPs welcome the referral path; others may resist if they perceive the upstream workup as unnecessary. A polite, direct request for a referral usually resolves it.

For complex findings, our concierge service can coordinate U.S.-side follow-up: re-read by a U.S. radiologist, translation of any Mandarin clinical notes, direct DICOM transfer to a U.S. cardiologist or oncologist of the patient's choice.

What insurance still won't fix

Some preventive needs require travel — but others are genuinely better handled at home:

• Stay in the U.S. if you're symptomatic, have an active condition under specialist care, or have insurance that covers what you need under existing coverage rules
• Consider Taiwan if you're asymptomatic, want a structured baseline, have family history that doesn't meet U.S. risk thresholds, or are paying cash anyway and the U.S. number is prohibitive
• Always coordinate with your U.S. primary care physician — they'll receive the report and can integrate findings into your ongoing care

For more on the AI-assisted reading workflow that drives findings accuracy at our partner facilities, see our piece on AI-augmented screening accuracy. For why one-stop centers outperform fragmented systems, read about Taiwan's one-stop medical model. For the dollar mechanics — HSA eligibility, FSA rules, what insurance reimburses post-trip — our companion cost & insurance article covers the financial side of the same decision.

To compare specific package contents, browse our screening packages, view partner providers, or chat with a concierge to map your family history and goals to the right protocol.

Sources & Further Reading

• USPSTF — U.S. Preventive Services Task Force recommendations
• American Cancer Society — Cancer Facts & Figures
• NCI SEER — Surveillance, Epidemiology, and End Results Program
• CDC — Cancer prevention & screening
• American Heart Association — heart attack risk
• American College of Cardiology — clinical guidelines

Frequently asked questions